Chemical Structure : Moxetumomab
CAS No.:
货号: PC-Ab1113Not For Human Use, Lab Use Only.
Moxetumomab pasudotox is an anti-CD22 monoclonal antibody fused to a 38 kDa fragment of Pseudomonas exotoxin A, PE38. Moxetumomab binds to CD22 on HCL cells and leads to apoptotic cell death after internalization and trafficking of the toxin to the cytosol. CD22 is a single chain integral membrane molecule and a member of the immunoglobulin gene superfamily, an inhibitory B lymphocyte receptor specifically recognizing α2,6 sialic acids. It functions as an adhesion receptor and a signaling molec
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥3580 | In stock | |
5 mg | ¥7580 | In stock | |
10 mg | ¥12800 | In stock | |
100 mg | Get quote |
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Moxetumomab pasudotox is an anti-CD22 monoclonal antibody fused to a 38 kDa fragment of Pseudomonas exotoxin A, PE38. Moxetumomab binds to CD22 on HCL cells and leads to apoptotic cell death after internalization and trafficking of the toxin to the cytosol. CD22 is a single chain integral membrane molecule and a member of the immunoglobulin gene superfamily, an inhibitory B lymphocyte receptor specifically recognizing α2,6 sialic acids. It functions as an adhesion receptor and a signaling molecule, which appears to be involved in regulating the expression of surface IgM on peripheral B-cells and Ca++ flux in response to immunoglobulin signaling.
分子量 | ||
分子式 | Human IgG1-Kappa | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
PBS, pH 7.0 Contains no stabilizers or preservatives |
|
Chemical Name/SMILES |
Moxetumomab; Anti-human CD22; Anti-human Siglec-2; Anti-human sialic acid binding Ig-like lectin 2 |
1. 1, Kreitman RJ, et al. Leukemia. 2018 Aug;32(8):1768-1777. 2, Fancher KM, et al. J Oncol Pharm Pract. 2019 Sep;25(6):1467-1472. 3, Lin AY, et al. Blood Adv. 2019 Oct 8;3(19):2905-2910. 4, Kreitman RJ, et al. J Pharm Sci. 2020 Sep;109(9):2676-2683.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright